Autologous hematopoietic stem cell transplantation in multiple sclerosis
A phase II trial
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 7, 2014
- Accepted in final form October 15, 2014
- First Published February 11, 2015.
Article Versions
- Previous version (February 11, 2015 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Giovanni L. Mancardi, MD,
- Maria P. Sormani, MD,
- Francesca Gualandi, MD,
- Albert Saiz, MD,
- Eric Carreras, MD,
- Elisa Merelli, MD,
- Amedea Donelli, MD,
- Alessandra Lugaresi, MD,
- Paolo Di Bartolomeo, MD,
- Maria R. Rottoli, MD,
- Alessandro Rambaldi, MD,
- Maria P. Amato, MD,
- Luca Massacesi, MD,
- Massimo Di Gioia, MD,
- Luisa Vuolo, MD,
- Daniela Currò, MD,
- Luca Roccatagliata, MD,
- Massimo Filippi, MD,
- Umberto Aguglia, MD,
- Pasquale Iacopino, MD,
- Dominique Farge, MD,
- Riccardo Saccardi, MD;
- For the ASTIMS Haemato-Neurological Collaborative Group, On behalf of the Autoimmune Disease Working Party (ADWP) of the European Group for Blood and Marrow Transplantation (EBMT)
- Giovanni L. Mancardi, MD,
NONE
NONE
Honoraria for lecturing , travel expenses for attending meetings and finacial support for research from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi- Aventis and Teva Pharmaceuticals
Associate Editor of Neurological Sciences
NONE
NONE
Honoraria for speaking activities from Companies (Biogen Dompe', Bayer Schering)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Italian Multiple Sclerosis Society (AISM) Grants 2001-R-38 and 2002-R-36
NONE
NONE
NONE
NONE
NONE
NONE
- Maria P. Sormani, MD,
Commercial entity: BIOGEN IDEC, TEVA
NONE
Merck Serono, TEVA, Genzyme, Novartis, Biogen Idec, Synthon, Roche
NONE
NONE
NONE
NONE
Merck Serono, Actelion, Biogen Idec, Synthon, TEVA, Novartis
Teva, Merck Serono, Biogen Idec, Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Francesca Gualandi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Albert Saiz, MD,
(1) Biogen Idec, (2) Merck-Serono
NONE
(1) Bayer-Schering, (2) Merck-Serono, (3) Biogen Idec, (4) Sanofi-Aventis, (5) Teva Pharmaceutical Industries, (6) Novartis
NONE
NONE
NONE
NONE
(1) Bayer-Schering, (2) Merck-Serono, (3) Biogen-Idec, (4) Sanofi-Aventis, (5) Teva Pharmaceutical Industries, (6) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eric Carreras, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elisa Merelli, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Amedea Donelli, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alessandra Lugaresi, MD,
1. Merck Serono
NONE
1)Bayer, 2)Biogen Idec, 3)Merck Serono, 4)Novartis, 5) Sanofi-Genzyme, 6)Teva, 7) Fondazione Italiana Sclerosi Multipla.
NONE
NONE
NONE
NONE
1)Bayer, 2)Biogen Idec, 3)Merck Serono, 4)Novartis, 5) Sanofi-Genzyme and 6)Fondazione
NONE
Fondazione Italiana Sclerosi Multipla, non profit observational and interventional studies
NONE
(1) Bayer (2) Biogen Idec (3) Merck Serono (4) Sanofi (5) Novartis (6) Teva
NONE
NONE
(1) AISM (Associazione Italiana Sclerosi Multipla),
NONE
NONE
NONE
NONE
NONE
NONE
- Paolo Di Bartolomeo, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria R. Rottoli, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen, 2008, 2009, 2013 (2) Bayer Shering, 2009, 2013 (3) Merck Serono, 2009, 2013 (4) Sanofi Aventis, 2008
NONE
NONE
NONE
NONE
NONE
NONE
- Alessandro Rambaldi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria P. Amato, MD,
member of Advisory Boards for Biogen-Idec, Merck Serono, Teva, Novartis, Sanofi Aventis, Genzyme and Almirall
NONE
honoraria for speaking from Biogen-Idec, Merck Serono, Novartis , Teva, Genzyme, Almirall and Sanofi Aventis
Member of Editorial Board and Associate Editor of BMC Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
research grants from Biogen Idec, Merk Serono, Bayer Shering, Sanophi Aventis, Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luca Massacesi, MD,
NONE
NONE
1) Commercial entity Biogen-Idec: travel grant for two scientific events; 2) commercial entity Merck Serono: travel grant for two scientific events; 3) commercial entity Genzyme: travel grant for two scientific events.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Massimo Di Gioia, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luisa Vuolo, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Daniela Currò, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luca Roccatagliata, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Massimo Filippi, MD,
TEVA
NONE
Bayer-Schering, Biogen-Idec, Merck-Serono, Teva
Editor in CHief, Journal of Neurology. Editorial Board Member: AJNR, BMC Musculoskeletal Disorders, Clinical Neurology and Neurosurgery, Erciyes Medical Journal, Journal of Alzheimer's Disease, Journal of Neuroimaging, Journal of Neurovirology, Lancet Neurology, Magnetic Resonance Imaging, Multiple Sclerosis, Neurological Sciences
NONE
NONE
NONE
Bayer-Schering, Biogen-Idec, Merck-Serono, Novartis, Teva
Bayer-Schering, Biogen-Idec, Merck-Serono, Teva.
NONE
NONE
1) Commercial entity: Bayer-Schering 2) Commercial entity: Biogen-Idec 3) Commercial entity: Merck-Serono 4) Commercial entity: Novartis 5) Commercial entity: Teva
1) Italian Ministry of Health; grant number: RF-2010- 2313220; role: P.I.; duration: December 2012-November 2015
NONE
1) Fondazione Italiana Sclerosi Multipla (FISM) 2) CurePSP 3) The Gossweiler Foudation (Switzerland) 4) Alzheimer's Drug Discovery Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Umberto Aguglia, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pasquale Iacopino, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Dominique Farge, MD,
NONE
NONE
NONE
EDITOR IN CHEEF OF PATHOLOGY BIOLOGY
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Riccardo Saccardi, MD;
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- For the ASTIMS Haemato-Neurological Collaborative Group, On behalf of the Autoimmune Disease Working Party (ADWP) of the European Group for Blood and Marrow Transplantation (EBMT)
- From the MRI Center for Neurological Diseases (L.R.), Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health (G.L.M., D.C.), and the Biostatistic Unit, Department of Health Sciences (M.P.S., L.R.), University of Genova; the Bone Marrow Transplantation Unit (F.G.), S. Martino Hospital, Genova, Italy; the Service of Neurology (A.S.) and the Hematology Department (E.C.), Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer, Hospital Clínic, University of Barcelona, Spain; the Department of Neurosciences (E.M.) and the Bone Marrow Transplantation Unit, Department of Hematology and Oncology (A.D.), University of Modena and Reggio Emilia; the MS Center, Department of Neuroscience, Imaging and Clinical Sciences (A.L.), University Gabriele D'Annunzio, Chieti-Pescara; the Bone Marrow Transplant Center, Department of Hematology (P.D.B.), Spirito Santo Hospital, Pescara; the Multiple Sclerosis Unit Ospedale Papa Giovanni XXIII (M.R.R.), Bergamo; the Hematology and Bone Marrow Transplant Unit Azienda Ospedaliera Papa Giovanni XXIII (A.R.), Bergamo; Division Neurology 1 (M.P.A.) and Division Neurology 2, Drug and Child Health (L.M., L.V.), Department of Neurosciences, and Bone Marrow Transplantation Unit (M.D.G., R.S.), Careggi University Hospital, University of Firenze; the Neuroimaging Research Unit (M.F.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan; the Department of Medical and Surgical Sciences (U.A.), Magna Graecia University of Catanzaro; the Advanced Cellular Therapy Center IRCCS “Istituto Tumori Giovanni Paolo II” Bari (P.I.), Italy; and the Internal Medicine and Vascular Disease Unit (D.F.), Assistance Publique Hospitaux de Paris (AP-HP) INSERM U 796, Paris 7 University, Saint-Louis Hospital, Paris, France.
- Correspondence to Dr. Mancardi: glmancardi{at}neurologia.unige.it
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- Remarks/A phase I trial?
- Roberto Vasselli, Varese, Italyvasselli@alice.it
Submitted August 03, 2015
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.